Cargando…
Asthma-associated risk for COVID-19 development
The newly described severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for a pandemic (coronavirus disease 2019 [COVID-19]). It is now well established that certain comorbidities define high-risk patients. They include hypertension, diabetes, and coronary artery disease. In...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Academy of Allergy, Asthma & Immunology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834224/ https://www.ncbi.nlm.nih.gov/pubmed/33002516 http://dx.doi.org/10.1016/j.jaci.2020.09.017 |
_version_ | 1783642234959167488 |
---|---|
author | Skevaki, Chrysanthi Karsonova, Antonina Karaulov, Alexander Xie, Min Renz, Harald |
author_facet | Skevaki, Chrysanthi Karsonova, Antonina Karaulov, Alexander Xie, Min Renz, Harald |
author_sort | Skevaki, Chrysanthi |
collection | PubMed |
description | The newly described severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for a pandemic (coronavirus disease 2019 [COVID-19]). It is now well established that certain comorbidities define high-risk patients. They include hypertension, diabetes, and coronary artery disease. In contrast, the context with bronchial asthma is controversial and shows marked regional differences. Because asthma is the most prevalent chronic inflammatory lung disease worldwide and SARS-CoV-2 primarily affects the upper and lower airways leading to marked inflammation, the question arises about the possible clinical and pathophysiological association between asthma and SARS-CoV-2/COVID-19. Here, we analyze the global epidemiology of asthma among patients with COVID-19 and propose the concept that patients suffering from different asthma endotypes (type 2 asthma vs non–type 2 asthma) present with a different risk profile in terms of SARS-CoV-2 infection, development of COVID-19, and progression to severe COVID-19 outcomes. This concept may have important implications for future COVID-19 diagnostics and immune-based therapy developments. |
format | Online Article Text |
id | pubmed-7834224 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Academy of Allergy, Asthma & Immunology |
record_format | MEDLINE/PubMed |
spelling | pubmed-78342242021-01-26 Asthma-associated risk for COVID-19 development Skevaki, Chrysanthi Karsonova, Antonina Karaulov, Alexander Xie, Min Renz, Harald J Allergy Clin Immunol Reviews and Feature Article The newly described severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for a pandemic (coronavirus disease 2019 [COVID-19]). It is now well established that certain comorbidities define high-risk patients. They include hypertension, diabetes, and coronary artery disease. In contrast, the context with bronchial asthma is controversial and shows marked regional differences. Because asthma is the most prevalent chronic inflammatory lung disease worldwide and SARS-CoV-2 primarily affects the upper and lower airways leading to marked inflammation, the question arises about the possible clinical and pathophysiological association between asthma and SARS-CoV-2/COVID-19. Here, we analyze the global epidemiology of asthma among patients with COVID-19 and propose the concept that patients suffering from different asthma endotypes (type 2 asthma vs non–type 2 asthma) present with a different risk profile in terms of SARS-CoV-2 infection, development of COVID-19, and progression to severe COVID-19 outcomes. This concept may have important implications for future COVID-19 diagnostics and immune-based therapy developments. American Academy of Allergy, Asthma & Immunology 2020-12 2020-09-28 /pmc/articles/PMC7834224/ /pubmed/33002516 http://dx.doi.org/10.1016/j.jaci.2020.09.017 Text en © 2020 American Academy of Allergy, Asthma & Immunology. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Reviews and Feature Article Skevaki, Chrysanthi Karsonova, Antonina Karaulov, Alexander Xie, Min Renz, Harald Asthma-associated risk for COVID-19 development |
title | Asthma-associated risk for COVID-19 development |
title_full | Asthma-associated risk for COVID-19 development |
title_fullStr | Asthma-associated risk for COVID-19 development |
title_full_unstemmed | Asthma-associated risk for COVID-19 development |
title_short | Asthma-associated risk for COVID-19 development |
title_sort | asthma-associated risk for covid-19 development |
topic | Reviews and Feature Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834224/ https://www.ncbi.nlm.nih.gov/pubmed/33002516 http://dx.doi.org/10.1016/j.jaci.2020.09.017 |
work_keys_str_mv | AT skevakichrysanthi asthmaassociatedriskforcovid19development AT karsonovaantonina asthmaassociatedriskforcovid19development AT karaulovalexander asthmaassociatedriskforcovid19development AT xiemin asthmaassociatedriskforcovid19development AT renzharald asthmaassociatedriskforcovid19development |